Seven vital questions about RNA Covid-19 vaccines

Standfirst

Both the Pfizer-BioNTech and Moderna Covid-19 vaccines, unlike the vaccines we already use for other diseases, have been developed using ribonucleic acid (RNA) technology. So, how do they work, are they safe, and what else do we know about them? 

Listing image
Hand holding a vaccine next to a sequence of messenger RNA genetic code
Credit
Wellcome
Title
Seven vital questions about RNA Covid-19 vaccines
File size
371805 bytes
Image width
1200px
Image height
674px
Filename
seven-vital-questions-about-the-rna-covd-19-vaccines.jpg
Image
Hand holding a vaccine next to a sequence of messenger RNA genetic code
Download allowed
On
Content
Group title
1. How do the vaccines work?
Admin title
1. How do the vaccines work?
Group
Body

RNA, closely related to DNA, is present in all living cells. The strand of it called messenger RNA is a sequence of genetic code that tells cells what proteins to build so that they can function. 

To produce an RNA vaccine, scientists develop a synthetic version of some of the virus’ messenger RNA. 

When this is injected into the human body, our cells read it as an instruction to start building the proteins, including, in this case, Covid-19's distinctive 'spike' protein.

Our bodies then mount an immune response by producing antibodies to fight the virus proteins made by our cells. This prepares our immune system to fight the real virus if we encounter it later on. 

This is different to the way some other vaccines work, where a small part of the virus itself, or the whole virus (weakened or dead), is injected into the body to trigger an immune response. 

Image
Graphic showing how RNA vaccines work
Caption

A synthetic version of part of the virus' genetic code is injected. It tells our cells to start building the virus protein, triggering an immune response.

File size
1691228 bytes
Image width
3333px
Image height
3333px
Filename
how-rna-vaccines-work.jpg
Image
Graphic showing how RNA vaccines work
Download allowed
On
Group title
2. How is RNA vaccine development different to other vaccine development?
Admin title
2. How is RNA vaccine development different to other vaccine development?
Group
Body

RNA vaccines hold the promise of being faster, cheaper, more adaptable and easier to mass-produce than other vaccines, because:

  • They can be generated quickly. RNA vaccines are based on a process of biochemical synthesis that involves fewer components and fewer steps than the more complex traditional methods, like using inactivated live viruses. This means they are quicker to get into clinical trials and quicker to manufacture once the trials are completed – in a matter of weeks and months. 
  • They should be cheaper to develop. Only a small amount of RNA needs to be delivered into the body’s cells, compared to the much larger micrograms of protein that are required for many other vaccines. This means each individual vaccine dose should be cheaper to purchase, although it is dependent on the price set by pharmaceutical companies and the costs of delivery.
  • They could be more adaptable and easier to manufacture at scale. The same RNA vaccine platform could be used to produce vaccines against different diseases – both known and emerging. A manufacturing plant could, in theory, produce multiple vaccines using the platform, whereas other vaccines, such as MMR (measles, mumps, and rubella) and Ervebo (one of the Ebola vaccines), each require their own dedicated manufacturing plant.
Group title
3. Have there been any other RNA vaccines?
Admin title
3. Have there been any other RNA vaccines?
Group
Body

The Pfizer-BioNTech and Moderna vaccines are the first RNA vaccines ever to be approved for use against any disease.

However, researchers have been using the technology for a while, and people have been given RNA vaccines in clinical trials for other diseases, like cancer.

A major challenge in the past has been figuring out how to deliver the RNA vaccine into the cell so it survives – our bodies naturally want to destroy foreign RNA molecules. 

This new use of RNA has only been made possible due to the enormous level of research funding and focus during the pandemic, which has allowed breakthroughs in new technologies. The cutting-edge method could revolutionise vaccine development for future disease outbreaks.

Group title
4. Are the vaccines safe?
Admin title
4. Are the vaccines safe?
Group
Body

Before any vaccine can be approved for use it must go through rigorous testing, to make sure it is safe, as well as effective. 

Around 43,500 people were enrolled in the Pfizer-BioNTech clinical trials, and 30,000 people in the Moderna clinical trials. Safety has been assessed throughout, and no major side-effects have been reported during the phase I, II and III trials.

Once the trials are complete and the full data has been analysed, regulators around the world review it and decide whether the vaccines can be approved for use in their countries. They look at all the preclinical, clinical and manufacturing process data, including the safety and efficacy data. 

Once approved, the vaccines will be monitored as they are given to prioritised high-risk groups, to understand how they perform in different population groups over time, and to look for very rare side-effects or long-term safety issues. Of the millions who have received the vaccines so far, a few people have had a very rare allergic reaction.

Nothing in medicine is 100% safe, and very rare side-effects may emerge as millions of people are vaccinated. This is the same for all vaccines. 

Group title
5. How many doses will be manufactured this year?
Admin title
5. How many doses will be manufactured this year?
Group
Body

Pfizer-BioNTech have said that they will be able to supply around 1.3 billion doses by the end of 2021. 

Moderna has said it intends to manufacture between 600 million and one billion doses throughout 2021. 

However, these vaccines are far from being the only hope: there are currently more than 320 Covid-19 vaccine candidates in development. The Oxford/AstraZeneca viral vector vaccine has been approved for use in the UK by the Medicines and Healthcare products Regulatory Authority, with more countries due to follow.

Group title
6. What are the potential limitations of the vaccines?
Admin title
6. What are the potential limitations of the vaccines?
Group
Body

The announcements are really positive news, especially as both vaccines have shown efficacy of around 95% in phase III clinical trials. But there are still many outstanding questions, for example how long immunity will last for, how effective the vaccines will be in different populations, and whether people can still transmit the disease to others if they’ve been immunised.

Pfizer-BioNTech has reported high levels of vaccine efficacy in over 65 year olds – one of the groups most at risk of serious illness – which is very promising. 

Although many vaccines need to be refrigerated – usually around 2 to 8C – the Pfizer-BioNTech Covid-19 vaccine needs to be stored at at least -70C, which could pose problems for transporting and storing it, particularly in low- and middle-income countries where refrigeration facilities may be limited.

The Moderna vaccine can be stored at fridge temperature for 30 days (2 to 8C) once delivered to healthcare facilities which is encouraging, but requires -20C for long-term storage and transportation.

It is critical that we continue with efforts to ensure fair access to Covid-19 vaccines, for example through the COVID-19 Vaccine Global Access Facility (COVAX). This will be instrumental to ensuring effective vaccines are prioritised for those most in need around the world.

Group title
7. Why do we need to continue to invest in different vaccine approaches?
Admin title
7. Why do we need to continue to invest in different vaccine approaches?
Group
Body

Two Covid-19 vaccines won’t be enough. The world needs a range of vaccines that have different characteristics, are suitable for people of all ages and ethnic groups – including people with underlying health conditions, and able to be distributed and used in all settings around the globe. They must also be available in the billions of doses. One or two vaccines won't be able to achieve this, and so we must continue to develop multiple vaccines using multiple scientific approaches to be able to control the pandemic.

Over the past decade we’ve seen the health and economic impact of influenza, SARS, Zika, Ebola and now Covid-19. There are certainly more outbreaks to come, but we don’t know when and where they will emerge, which makes preparation difficult. If we can hone new methods of developing vaccines, we’ll be much better prepared for any future outbreaks and able to save more lives with vaccines, faster.

That is why the urgent funding gaps in the global response to Covid-19 must be addressed. Only through appropriate funding can innovations like RNA vaccines be made possible.

This explainer was first published on 13 November 2020.

Group title
Related content
Group
Listing layout
Image card with CTA link (Horizontal card)
Content
Body
There are hundreds of Covid-19 vaccines in development, and some have produced very positive results in phase III clinical trials. How do some of the different vaccines work and compare?
Title
What different types of Covid-19 vaccine are there?
Content type
Explainer
Published date
Modified date
Image
Four cartoon test tubes with virus and dna symbols in each.
Credit
Wellcome
Title
What different types of Covid-19 vaccine are there?
File size
390907 bytes
Image width
1600px
Image height
900px
Filename
FINAL_ExplainerThumbnails_Ex9_What_Different_Types_Of_Covid_Vaccine_Are_There-1600x900_0.png
Image
Four cartoon test tubes with virus and dna symbols in each.
Download allowed
On
Body
We want to help the world overcome Covid-19. Research is the best way to save lives – but more investment in accessible treatments, tests and vaccines is urgently needed to change the course of the pandemic.
Title
Coronavirus (Covid-19): supporting global research and development
Published date
Modified date
Image
A map of the world, a hand holding a test tube and three children washing their hands
File size
866480 bytes
Image width
3333px
Image height
1204px
Filename
coronavirus-covid-19-supporting-global-research-and-development-1600px_0.jpg
Image
A map of the world, a hand holding a test tube and three children washing their hands
Download allowed
On
Listing summary
Both the Pfizer-BioNTech and Moderna Covid-19 vaccines, unlike the vaccines we already use for other diseases, have been developed using ribonucleic acid (RNA) technology. So, how do they work, are they safe, and what else do we know about them? 
Banner styling
Compact
Banner image
Hand holding a vaccine next to a sequence of messenger RNA genetic code
Credit
Wellcome
File size
371805 bytes
Image width
1200px
Image height
674px
Filename
seven-vital-questions-about-the-rna-covd-19-vaccines.jpg
Image
Hand holding a vaccine next to a sequence of messenger RNA genetic code
Download allowed
On
Exclude from listings
Off
Meta title
Seven vital questions about the RNA Covid-19 vaccines emerging from clinical trials | News | Wellcome
Meta description
The Pfizer-BioNTech and Moderna Covid-19 vaccines have been developed using ribonucleic acid (RNA) technology. So, how do they work, are they safe, and when will they be available? 
Ordering date
Article type
Explainer
Published date
Article content type
News
Add noindex
Off
Statement
Off
6 minutes